TTM
−$36.45M
YoY change
-26.2%
5Y CAGR
—
Peak year (2018)
−$9.97M
Cumulative EBITDA
−$290.42M
EBITDA history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: −$38.85M
EBITDA growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: -26.2%
EBITDA history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | −$38.85M | -26.2% | +$13.83M | ||
| 2024 | −$52.68M | +11.2% | −$5.32M | ||
| 2023 | −$47.37M | +3.7% | −$1.68M | ||
| 2022 | −$45.69M | +9.1% | −$3.81M | ||
| 2021 | −$41.88M | +42.5% | −$12.50M | ||
| 2020 | −$29.38M | +125.8% | −$16.37M | ||
| 2019 | −$13.01M | +30.5% | −$3.04M | ||
| 2018 | −$9.97M | — | — |
- 2025−$38.85M-26.2%
- 2024−$52.68M+11.2%
- 2023−$47.37M+3.7%
- 2022−$45.69M+9.1%
- 2021−$41.88M+42.5%
- 2020−$29.38M+125.8%
- 2019−$13.01M+30.5%
- 2018−$9.97M—
EBITDA values are taken from Spruce Biosciences's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Spruce Biosciences (SPRB)
According to Spruce Biosciences's latest reported financial statements, the company's current EBITDA (TTM) is −$36.45M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Spruce Biosciences (SPRB) most recent annual EBITDA stands at −$38.85M (2025) – declined 26.2% year-over-year.
−$9.97M stands as the all-time-high annual EBITDA, posted in 2018, against a low of −$52.68M during 2024.
Spruce Biosciences EBITDA by Year
Spruce Biosciences EBITDA 2025: −$38.85M
2025's EBITDA for Spruce Biosciences came in at −$38.85M, declined 26.2% below 2024.
Spruce Biosciences EBITDA 2024: −$52.68M
Spruce Biosciences posted EBITDA of −$52.68M in 2024, grew 11.2% from 2023. This figure represents the lowest annual value in the available history.
Spruce Biosciences EBITDA 2023: −$47.37M
In 2023, Spruce Biosciences reported EBITDA of −$47.37M, edged up 3.7% from 2022.
Spruce Biosciences EBITDA 2022: −$45.69M
Spruce Biosciences EBITDA in 2022 was −$45.69M, grew 9.1% from 2021.
Spruce Biosciences EBITDA 2021: −$41.88M
Spruce Biosciences EBITDA in 2021 was −$41.88M.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by EBITDA
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation